Cholesterol drugs called PCSK9 inhibitors lower the relative risk of heart attacks by about 25% compared with placebo.
From We Are Witnessing The End of Heart Attacks · videoSee the scientific wording
PCSK9 inhibitors, compared with placebo, reduce the RELATIVE risk of heart attacks by approximately 25% (a relative risk reduction of about a quarter); the absolute risk reduction is not reported.
Partly true
ObservationalNo study measured the main part of this claim. 2 of 4 parts have evidence behind them.
Partly true
No study measured the main part of this claim. 2 of 4 parts have evidence behind them.
Parts of this claim
PCSK9 inhibitors inhibit PCSK9.
Not testedNo studiesPCSK9 inhibitors reduce the relative risk of heart attacks by about 25% compared with placebo.
Supported1 studyPCSK9 inhibitors reduce the relative risk of strokes by about 25% compared with placebo.
Unclear1 studyPCSK9 inhibitors reduce the relative risk of coronary deaths by about 25% compared with placebo.
Not testedNo studies
Evidence is judged against each part on its own, so a study that tests one part never counts as a verdict on the whole claim.
What the research says
2 studies reviewedSupporting (2)
Cohort StudyHuman2023
In this study, people who received a PCSK9 inhibitor (alirocumab) had about 28% fewer heart attacks, strokes, or heart-related deaths than those who received placebo, which is close to the 25% reduction claimed.
Cohort StudyHuman2026
PCSK9 inhibitor drugs did lower heart attacks and deaths in this study, but the drop was smaller than 25% for heart attacks, and strokes were not reduced. So the claim is in the right direction but too strong.
Contradicting (0)
No contradicting studies found yet
That doesn't mean it's settled — it just means no study has tested the opposite.
Quality-weighted scoring: we follow the GRADE framework — each study is rated High, Moderate, Low, or Very Low based on study design, methodology rigor, and risk of bias. A single high-quality RCT can outweigh several weaker observational studies.
Scores reflect study quality, not just count.
PCSK9 inhibitors stop a protein called PCSK9 from breaking down LDL receptors on liver cells. With more LDL receptors, the liver pulls more bad cholesterol out of the blood. Less bad cholesterol in the blood means less fatty buildup in artery walls. Less buildup means arteries stay clearer, so fewer heart attacks, strokes, and heart-related deaths.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 2 supporting studies
Related videos
How Fit Body Science checks a claim
- 1
We isolate the claim
Health advice from videos, articles and studies is broken down into single, testable claims.
- 2
We find the research
Each claim is matched against peer-reviewed studies, with every source cited by DOI.
- 3
We grade the evidence
Studies are scored on methodology, statistical rigor, transparency and publication quality.
The fitness and health internet is full of confident claims. We check them against real research.
Every claim on this site is traced back to peer-reviewed studies, scored on methodology and reporting quality, and given a verdict you can audit yourself — sources, DOIs and all.
- Full evidence breakdown and mechanism chains
- Ask our AI anything about a claim or its studies
- Get notified when new research changes a verdict
Cholesterol drugs called PCSK9 inhibitors lower the relative risk of heart attacks by about 25% compared with placebo.
Mechanism
2 studiesPCSK9 inhibitors stop a protein that normally destroys cholesterol-clearing receptors in the liver. With more receptors, the liver removes more bad cholesterol from the blood. Less bad cholesterol means less fatty plaque in arteries, so fewer heart attacks and heart-related deaths. The effect on strokes is smaller, showing that other factors also matter for strokes.
PCSK9 inhibitors stop a protein called PCSK9 from breaking down LDL receptors on liver cells. With more LDL receptors, the liver pulls more bad cholesterol out of the blood. Less bad cholesterol in the blood means less fatty buildup in artery walls. Less buildup means arteries stay clearer, so fewer heart attacks, strokes, and heart-related deaths.
PCSK9 inhibitors bind to circulating PCSK9 protein and block its interaction with hepatic LDL receptors.
Hepatic LDL receptors avoid PCSK9-mediated degradation and are recycled back to the hepatocyte cell surface.
Increased LDL receptor density on hepatocytes enhances the clearance of LDL cholesterol from the bloodstream.
Plasma LDL cholesterol concentration decreases.
Lower LDL cholesterol reduces lipid deposition and inflammatory cell recruitment within the arterial intima.
Atherosclerotic plaques develop a smaller lipid core and a thicker fibrous cap, increasing plaque stability.
Stable plaques are less prone to rupture and erosion, reducing exposure of thrombogenic core material to blood.
Reduced plaque rupture and thrombosis decrease the incidence of acute myocardial infarction, ischemic stroke, and coronary death.
Evidence from Studies
Last searched 4d ago
Supporting (2)
Community contributions welcome
In this study, people who received a PCSK9 inhibitor (alirocumab) had about 28% fewer heart attacks, strokes, or heart-related deaths than those who received placebo, which is close to the 25% reduction claimed.
PCSK9 inhibitor drugs did lower heart attacks and deaths in this study, but the drop was smaller than 25% for heart attacks, and strokes were not reduced. So the claim is in the right direction but too strong.
Contradicting (0)
Community contributions welcome
Score Breakdown
No multi-axis breakdown available yet. The overall Pro / Against score above is the best signal.
- No clinical evidence is available; the score reflects mechanistic plausibility only.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Meta-Analysis of Randomized PCSK9 Inhibitor Trials for Heart Attack Risk
Systematic review and meta-analysis of double-blind, placebo-controlled RCTs of PCSK9 inhibitors (e.g., alirocumab, evolocumab) in adults with hypercholesterolemia or high cardiovascular risk; primary outcome: myocardial infarction; follow-up ≥2 years; report relative risk and absolute risk difference.
Double-Blind Placebo-Controlled RCT of PCSK9 Inhibitor for Myocardial Infarction Prevention
Randomized, double-blind, placebo-controlled trial in adults with established CVD or high LDL; intervention: PCSK9 inhibitor (e.g., evolocumab) vs placebo; primary outcome: fatal/nonfatal myocardial infarction; follow-up ≥2-5 years; report relative risk and absolute risk difference.
Prospective Cohort of PCSK9 Inhibitor Users vs Non-Users for Heart Attack Incidence
Prospective cohort of adults initiating PCSK9 inhibitors vs matched non-users or standard care; outcome: incident myocardial infarction; follow-up ≥3 years; adjust for confounders.
Case-Control Study of PCSK9 Inhibitor Use Among Heart Attack Cases vs Controls
Identify cases with myocardial infarction and matched controls; compare prior PCSK9 inhibitor use; adjust for confounders.
Expert Consensus Statement on PCSK9 Inhibitors and Heart Attack Risk Reduction
Delphi consensus or narrative review by lipidology/cardiology experts.